Activity of the new quinolone WCK 771 against pneumococci

Clinical Microbiology and Infection

Volumn 11, Issue 1, 2005, Pages 9-14

  Appelbaum, P C ^a   Pankuch, G A ^a   Bozdogan, B ^a   Lin, G ^a   Jacobs, M R ^b   Patel, M V ^c   Gupte, S V ^c   Jafri, M A ^c   De Souza, N J ^c   Khorakiwala, H F ^c  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c New Drug Discovery   (India)

Author keywords

Activity; New antibiotics; Quinolones; Streptococcus pneumoniae; WCK 771

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN; WCK 771;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SEPTICEMIA; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALIA; STAPHYLOCOCCI; STREPTOCOCCUS PNEUMONIAE;

EID: 13644260139     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.01017.x     Document Type: Article

References (35)

1. Thomson CJ. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob Chemother 1999; 43(suppl A): 31-40.
2. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002; 2: 530-538.
3. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77-83.
4. Jacobs MR. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1992; 15: 119-127.
5. Jacobs MR, Appelbaum PC. Antibiotic-resistant pneumococci. Rev Med Microbiol 1995; 6: 77-93.
6. Van Beneden CA, Lexau C, Baughman W et al. Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae. Emerg Infect Dis 2003; 9: 1089-1095.
7. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246.
8. McDougal LK, Facklam R, Reeves M et al. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob Agents Chemother 1992; 36 2176-2184.
9. Munoz R, Musser JM, Crain M et al. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis 1992; 15: 112-118.
10. Okeke IN, Edelman R. Dissemination of antibiotic-resistant bacteria across geographic borders. Clin Infect Dis 2001; 33: 364-369.
11. Friedland IR, Istre GR. Management of penicillin-resistant pneumococcal infections. Pediatr Infect Dis J 1992; 11: 433-435.
12. Friedland IR, McCracken CH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 3773-3782.
13. Hoellman DB, Lin G, Jacobs MR, Appelbaum PC. Antipneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J Antimicrob Chemother 1999; 43: 645-649.
14. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother 2000; 44 304-310.
15. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepaffoxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995; 35: 230-232.
16. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, WIN 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1992; 36: 856-859.
17. Spangler SK, Jacobs MR, Pankuch GA, Appelbaum PC. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. J Antimicrob Chemother 1993; 31: 273-280.
18. Visalli MA, Jacobs MR, Appelbaum PC. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996; 40 362-366.
19. Visalli MA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral β-lactams. Antimicrob Agents Chemother 1997; 41: 2786-2789.
20. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43: 1310-1313.
21. Chen DK, McCeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-239.
22. Liñares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999; 341 1546-1547.
23. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved Standard M7-A6. Wayne, PA: NCCLS, 2003.
24. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, fourteenth informational supplement. M100-S14. Wayne, PA: NCCLS, 2004.
25. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2032-2035.
26. Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 1177-1182.
27. Nagai K, Davies TA, Pankuch CA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 2740-2746.
28. Pankuch GA, Jacobs MR, Appelbaum PC. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother 1994; 38: 2065-2072.
29. 50 and its error by means of logarithmic-probit graph paper. Proc Soc Exp Biol Med 1994; 57: 261-264.
30. Litchfield JT, Wilcoxin F. A simplified method of evaluating dose-effect experiments. J Pharm Exp Ther 1949; 96: 99-113.
31. Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC and parE loci. Antimicrob Agents Chemother 1999; 43 329-334.
32. Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother 1999; 44: 621-627.
33. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999; 58: 11-18.
34. McCloskey L, Moore T, Niconovich N et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J Antimicrob Chemother 2000; 45(suppl 1): 13-21.
35. Gradelski E, Valera L, Kolek B, Bonner D, Fung-Tomc J. Comparative killing kinetics of the novel des-fluoro (6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. Int J Antimicrob Agents 2001; 18: 43-48.